# IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

> **NCT03981900** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 314 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT03981900
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2023-02-06
- **Final completion:** 2023-02-06
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981900, "IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03981900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*